Cambridge-based drug discovery company CN Bio has closed a $21m (£17m) Series B funding round to develop technology that it says eliminates the need for animal testing. The company specialises in organ-on-chip (OOC) technology, a process in which engineered or natural tissues are grown inside chips to mimic human physiology. CN Bio uses OOC tech […] Read this story
